Neurodegeneration in ataxia-telangiectasia is caused by horror autotoxicus

Medical Hypotheses

Volumn 52, Issue 5, 1999, Pages 377-382

  Kuljis, R O ^a   Aguila, M A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DNA; PROTEIN KINASE;

ANIMAL MODEL; ATAXIA TELANGIECTASIA; AUTOIMMUNITY; CEREBELLUM; DNA REPAIR; HUMAN; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALIA; ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0033064340     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1998.0771     Document Type: Article

References (50)

1. Louis-Bar D. Sur un syndrome progressif comprenant des télangiectasies capillaires cutanées et conjonctivales symétriques, à disposition naevoïde, et des troubles cérébelleux. Confinia Neurol. 4:1941;33-42.
2. Syllaba L., Henner K. Contribution a l'indépendance de l'atéthose double idiopathique et congénitale: atteinte familiale, syndrome dystrophique, signe du réseau vasculaire conjonctival, intégrité psyquique. Rev Neurol. 1:1926;541-562.
3. Boder E. Ataxia-telangiectasia: some historic, clinical and pathological observations. Birth Defects. 11:1975;255-270.
4. Bundey S. Clinical and genetic features of ataxia-telangiectasia. Int J Radiat Biol. 66:1994;S23-S29.
5. Sedgwick R. P., Boder E. Ataxia-telangiectasia. Vinken P., Bruyn G., Klawans H. Handbook of Clinical Neurology. 1991;347-423 Elsevier, Amsterdam.
6. Aguilar M. J., Kamoshita S., Landing B. H., Boder E. Pathological observations in ataxia-telangiectasia. A report on five cases. J Neuropathol Exp Neurol. 27:1968;659-676.
7. Strich S. Pathological findings in three cases of ataxia-telangiectasia. J Neurol Neurosurg Psychiatry. 29:1966;489-499.
8. Savitsky K., Bar-Shira S., Gilad G. A single ataxia-telangiectasia gene with a product similar to PI-3 kinase. Science. 268:1995;1749-1753.
9. Shiloh Y., Rotman G. Ataxia-telangiectasia and the ATM gene: linking neurodegeneration, immunodeficiency, and cancer cycle checkpoints. J Clin Immunol. 16:1996;254-260.
10. Savitsky K., Sfez S., Tagle D. A. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet. 4:1995;2025-2032.
11. Kastan M. Ataxia-telangiectasia: broad implications for a rare disorder. N Engl J Med. 333:1995;662-663.
12. Baskaran R., Wood L. D., Whitaker L. L. Ataxia telangiectasia mutant protein activates c-abl tyrosine kinase in response to ionizing radiation. Nature. 387:1997;516-519.
13. Xu Y., Ashley T., Brainerd E. E., Bronson R. T., Meyn S. M., Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10:1996;2411-2422.
14. Elson A., Wang Y., Daugherty C. J. Pleiotropic defects in ataxia-telangiectasia protein-deficiency mice. Proc Natl Acad Sci. 93:1996;13084-13089.
15. Barlow C., Hirotsune S., Paylor R. Atm-deficient mice: a paradigm of ataxia-telangiectasia. Cell. 86:1996;159-171.
16. Kuljis R. O., Xu Y., Aguila M. C., Baltimore D. Degeneration of neurons, synapses and neuropil, and glial activation, in a murine Atm knockout model of ataxia-telangiectasia. Proc Natl Acad Sci USA. 94:1997;12688-12693.
17. Peterson K., Rosenblum M. K., Kotanides H. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody positive patients. Neurology. 42:1992;1931-1937.
18. Posner J. B. Neurologic Complications of Cancer. 1995;F. A. Davis, Philadelphia.
19. Anderson N. E., Budde-Steffen C., Rosenblum M. K. Opsoclonus, myoclonus, ataxia and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine. 67:1988;100-109.
20. Dropcho E. J. Autoimmune central nervous system paraneoplastic disorders: mechanisms, diagnosis, and therapeutic options. Ann Neurol. 37:1995;S102-Sl13.
21. Teplitz R. L. Ataxia telangiectasia. Arch Neurol. 35:1978;553-554.
22. Ammann A. J., Hong R. Autoimmune phenomena in ataxia telangiectasia. J Pediatr. 78:1971;821-826.
23. Friedman J. M., Fialkow P. J., Davis S. D., Ochs H. D., Wedgwood R. J. Autoimmunity in the relatives of patients with immunodeficiency diseases. Clin Exp Immunol. 28:1977;375-388.
24. Berron P. R., Lopez H. A., Velasco C., Santana R. Ataxia telangectasia. Probability of damaging immune mechanisms. Bol Med Hosp Infant Mex. 34:1977;29-46.
25. Schulte-Wisserman H., Gutjahr P., Zebisch P., Reitz M., Lemmel E. M. Immunological investigations in two brothers with ataxia telangiectasia Louis-Bar. Eur J Pediatr. 122:1976;93-102.
26. Robinson S., Kessling A. Diabetes secondary to genetic disorders. Baillire's Clin Endocrinol Metab. 6:1992;867-898.
27. Bar R. S., Levis W. R., Rechler M. M. Extreme insulin resistance in ataxia telangiectasia: defect in affinity of insulin receptors. N Engl J Med. 298:1978;1164-1171.
28. Pelleitier M., Montplaisir S. The nude mouse: a model of deficient T-cell function. Methods Achiev Exp Pathol. 7:1975;149-166.
29. Tedeschi L. G., Tedeschi C. G. Ataxia in the neonatally thymectomized rat: a morphologic study of the central nervous system. J Neuropathol Exp Neurol. 27:1968;324-332.
30. Kaufman D. B., Miller H. C. Ataxia telangiectasia: an autoimmune disease associated with a cytotoxic antibody to brain and thymus. Clin Immunol Immunopathol. 7:1977;288-299.
31. Myozaki M., Wang M. Q., Yoshida Y., Liu J. N., Kuroda E., Yamashita U. Dysfunction of immune system and induction of autoantibodies to liver antigens by neonatal thymectomy in mice. Hiroshima J Med Sci. 45:1996;75-83.
32. Agamanolis D. P., Greenstein J. I. Ataxia-telangiectasia. Report of a case with Lewy bodies and vascular abnormalities within cerebral tissue. J Neuropathol Exp Neurol. 38:1979;475-489.
33. De Blas A. L., Kuljis R. O., Cherwinski H. M. Mammalian brain antigens defined by monoclonal antibodies. Brain Res. 322:1984;277-287.
34. Tanaka K., Tanaka M., Tsukamoto T., Uehara T., Tsuji S. Anti-Yo antibody binding to 62-, 52-, or 58-kd protein recognizes a single molecule. Neurology. 46:1996;1777-1778.
35. Tanaka K., Tanaka M., Igarashi S., Onodera O., Miyatake T., Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin Neurol Neurosurg. 97:1995;101-105.
36. Sakai K., Kitagawa Y., Ogasawara T., Hirose G. Expression of messenger RNA encoding a paraneoplastic cerebellar degeneration-associated antigen in the rat hippocampus. Neurosci Lett. 197:1995;33-36.
37. Sakai K., Gofuku M., Kitagawa Y., Ogasawara T., Hirose G. Induction of anti-Purkinje cell antibodies in vivo by immunizing with a recombinant 52-kDa paraneoplastic cerebellar degeneration-associated protein. J Neuroimmunol. 60:1995;135-141.
38. Greenlee J. E., Parks T. N., Jaeckle K. A. Type IIa ('anti-Hu') antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro. Neurology. 43:1993;2049-2054.
39. Greenlee J. E., Burns J. B., Rose J. W., Jaeckle K. A., Clawson S. Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption. Acta Neuropathol (Berl). 89:1995;341-345.
40. Verschuuren J., Chuang I., Rosenblum M. K. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol (Berl). 91:1996;519-525.
41. Corradi J. P., Yang C., Darnell J. C., Dalmau J., Darnell R. B. A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci. 17:1997;1406-1415.
42. Giometto B., Marchiori G. C., Nicolao P. Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol. 23:1997;468-474.
43. David Y. B., Warner E., Levitan M., Sutton D. M., Malkin M. G., Dalmau J. O. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer. 78:1996;2153-2156.
44. Tanaka M., Tanaka K., Onodera O., Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. Clin Neuro Neurosurg. 97:1995;95-100.
45. Biggar W. D., Good R. A. Immunodeficiency in ataxia-telangiectasia. Birth Defects. 11:1975;271-276.
46. Vinters H. V., Gatti R. A., Rakic P. Sequence of cellular events in cerebellar ontogeny relevant to expression of neuronal abnormalities in ataxia-telangiectasia. Kroc Foundation Series. 19:1985;233-255.
47. Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature. 314:1985;53.
48. Weiner J. A., Chun J. Maternally derived immunoglobulin light chain is present in the fetal mammalian CNS. J Neurosci. 17:1997;3148-3156.
49. Yuasa S. Developmental mechanisms of neural network in the cerebellar system. Nihon Shinkei Seishin Yakurigaku Zasshi. 15:1995;177-183.
50. Stark E., Wurster U., Patzold U., Sailer M., Haas J. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol. 52:1995;814-818.